Zacks Investment Research upgraded shares of Ignyta Inc (NASDAQ:RXDX) from a hold rating to a buy rating in a report issued on Saturday. The firm currently has $10.00 price target on the biopharmaceutical company’s stock.
According to Zacks, “Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. “
Separately, Jefferies Group LLC reiterated a buy rating and issued a $20.00 price target on shares of Ignyta in a research note on Wednesday, November 30th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Ignyta has a consensus rating of Buy and an average target price of $16.60.
Shares of Ignyta (NASDAQ:RXDX) traded down 1.75% during trading on Friday, reaching $8.40. 89,803 shares of the company traded hands. The firm has a 50 day moving average of $8.51 and a 200 day moving average of $6.71. Ignyta has a 52 week low of $4.15 and a 52 week high of $9.90. The stock’s market capitalization is $350.28 million.
ILLEGAL ACTIVITY WARNING: “Ignyta Inc (RXDX) Upgraded at Zacks Investment Research” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/04/21/ignyta-inc-rxdx-upgraded-by-zacks-investment-research-to-buy-updated-updated.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Great Point Partners LLC purchased a new position in shares of Ignyta during the third quarter worth about $21,859,000. Victory Capital Management Inc. purchased a new position in shares of Ignyta during the third quarter worth about $14,911,000. Armistice Capital LLC increased its position in shares of Ignyta by 36.6% in the fourth quarter. Armistice Capital LLC now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $10,600,000 after buying an additional 536,000 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in shares of Ignyta during the third quarter worth about $3,592,000. Finally, State Street Corp increased its position in shares of Ignyta by 7.8% in the fourth quarter. State Street Corp now owns 426,861 shares of the biopharmaceutical company’s stock worth $2,264,000 after buying an additional 30,833 shares in the last quarter. Institutional investors own 61.93% of the company’s stock.
Ignyta, Inc is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ignyta Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc and related companies with MarketBeat.com's FREE daily email newsletter.